Dose Escalation

Dose Escalation

Dose escalation is a fundamental strategy in clinical pharmacology in which patients begin treatment at a low dose that is incrementally increased at defined intervals until the target therapeutic dose is reached. This approach allows the body to gradually adapt to the drug’s effects, reducing the incidence and severity of adverse events that might occur if the full dose were administered from the outset. Dose escalation protocols are particularly important for drugs that affect gastrointestinal function, appetite regulation, or metabolic pathways, where abrupt pharmacological intervention can provoke significant side effects.

In the context of incretin-based therapies such as retatrutide, dose escalation is critical because GLP-1 receptor agonism commonly causes gastrointestinal side effects including nausea, vomiting, and diarrhea. By starting patients on a low dose and increasing gradually, typically at four-week intervals, clinicians can substantially improve tolerability. The Phase 2 retatrutide trials employed dose escalation schedules in which participants began at lower doses and titrated upward to their assigned maintenance dose over several weeks, which helped mitigate the gastrointestinal adverse events associated with the drug’s triple agonist mechanism.

Dose escalation also plays a central role in Phase 1 clinical trials, where single ascending dose and multiple ascending dose designs are used to determine the maximum tolerated dose and to characterize the dose-response relationship. The information gathered during these dose escalation studies directly informs the dose ranges selected for subsequent Phase 2 and Phase 3 trials, making it a foundational element of the drug development process.